TrialClinical breast cancer2009

A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.

Carolyn D Britten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.